Trillium Therapeutics Inc (TRIL)

[janetcanada]

Stem Cell Therapeutics touts NTx-265 journal paper


2010-03-10 15:22 ET - News Release

Dr. Alan Moore reports

STEM CELL THERAPEUTICS CORP. ANNOUNCES PUBLICATION OF PHASE IIA STROKE DATA

Stem Cell Therapeutics Corp. confirms the acceptance and publication of the paper entitled "The Beta-hCG plus Erythropoietin in Acute Stroke (BETAS) Study," by the journal Stroke on March 8, 2010. This paper was authored by Dr. Steven C. Cramer, from the University of California, Irvine, Dr. David Brown at Hoag Memorial Hospital Presbyterian, New Port Beach, Dr. Michael D. Hill of Foothills Hospital at the University of Calgary and colleagues.

Dr. Allen Davidoff, vice-persident of product development, commented as follows: "The Stroke journal, published by the American Heart Association, is the top journal in the field of stroke research. Stem Cell Therapeutics is pleased to congratulate Dr. Cramer, Dr. Brown and Dr. Hill for their efforts, acceptance and successful publication of this novel study by this highly respected, peer-reviewed journal. Previously this work has only appeared in abstracts. This publication marks another important milestone in the development of NTx-265 and provided the continued evidence of clinical safety and the foundation for the proof of concept study modified REGENESIS."